Aksoy Ahmet, Gulcu Anil, Tuna Mehmet Mert, Aslan Ahmet
Department of Orthopedics and Traumatology, Alanya Education and Research Hospital, Alanya, Turkey.
Department of Orthopedics and Traumatology, Medical School of Alaaddin Keykubat University, Alanya, Turkey.
Clin Med Insights Arthritis Musculoskelet Disord. 2022 Aug 23;15:11795441221118920. doi: 10.1177/11795441221118920. eCollection 2022.
The aim of this study was to present the clinical results of patients with Kellgren-Lawrence (KL) stage 2-4 hip osteoarthritis who were administered intra-articular corticosteroid (CS) or hyaluronic acid (HA), with or without fluoroscopy.
This retrospective comparative study was conducted in the clinics where the authors worked between 2010 and 2018. Patients with stage 2-4 hip osteoarthritis according to KL criteria were included in the study. Age, body mass index, American Society of Anesthesiologists stages, and Western Ontario and McMaster Universities Arthritis Index (WOMAC) scores (3rd, 6th, and 12th months) were recorded. Two groups were created as patients who underwent injection with or without fluoroscopy guidance. In group 1, CS (triamnisolone) was administered, and in group 2, sodium hyaluronate 88 mg/4 mL was administered. Obtained parameters were compared.
The WOMAC scores at 3 months of both the CS and HA groups were statistically significantly better than before the application, with the improvement in the CS group found to be significantly better than in the HA group ( = .047). At 6 months, the mean WOMAC scores of the CS and HA groups were better than prior to the application, and there was a statistically significant difference ( < .001). No significant difference was found in either the CS or HA group in the comparison of 12-month WOMAC scores with the baseline scores ( = .744 and = .054).
In symptomatic hip OA patients, intra-articular administration of CS and HA was seen to be effective at 3 and 6 months after administration. However, the effectiveness was determined to have disappeared within 1 year. Furthermore, in hip OA intra-articular drug applications, it was determined that the blinded technique without radiological guidance performed in the outpatient clinic is as effective and safe as the radiologically guided technique administered in the operating room.
本研究旨在呈现接受关节内注射皮质类固醇(CS)或透明质酸(HA)治疗的Kellgren-Lawrence(KL)2-4期髋骨关节炎患者的临床结果,注射过程有或无荧光透视引导。
本回顾性比较研究在作者于2010年至2018年工作的诊所中进行。纳入根据KL标准诊断为2-4期髋骨关节炎的患者。记录年龄、体重指数、美国麻醉医师协会分级以及西安大略和麦克马斯特大学骨关节炎指数(WOMAC)评分(第3、6和12个月)。根据是否在荧光透视引导下进行注射将患者分为两组。第1组注射CS(曲安奈德),第2组注射88 mg/4 mL透明质酸钠。对获得的参数进行比较。
CS组和HA组在注射后3个月时的WOMAC评分均在统计学上显著优于注射前,且CS组的改善明显优于HA组(P = 0.047)。在6个月时,CS组和HA组的平均WOMAC评分均优于注射前,且存在统计学显著差异(P < 0.001)。在比较12个月时的WOMAC评分与基线评分时,CS组和HA组均未发现显著差异(P = 0.744和P = 0.054)。
在有症状的髋骨关节炎患者中,关节内注射CS和HA在注射后3个月和6个月时显示出疗效。然而,这种疗效在1年内消失。此外,在髋骨关节炎的关节内药物应用中,确定在门诊进行的无放射学引导的盲注技术与在手术室进行的放射学引导技术一样有效和安全。